DEVELOPMENT AND CONDUCT OF MFI MULTI-CLIENT STUDIES Sample Clauses

DEVELOPMENT AND CONDUCT OF MFI MULTI-CLIENT STUDIES. (a) HBI will provide use of the HBI Database for the developmental phase of MFI Multi-Client Studies at the Use Fees, Access Fees, and/or Survey Fees charged to MFI pursuant to section 2.4(b) hereof. If use of the Association Database is required in connection with the developmental phase of the project, HBI will provide use of the Association Database for the Association Price, Association Use Fee, and Association Survey Fee applicable to such use according to Association Rules [Confidential Information. Intentionally omitted and filed separately with the Securities and Exchange Commission]. (b) MFI will have responsibility for, and shall bear the expenses related to, questionnaire design, the design of marketing materials, and the design of research deliverables for MFI Multi-Client Studies, subject to approval of HBI which will not be unreasonably withheld. Core demographic questions must be acceptable to HBI and demographic categories shall conform to categories then in use for the HBI Database. The final form of the survey must be approved by both parties; provided, however, that approval will not be unreasonably withheld by HBI. (c) In order to minimize the financial risk to the parties, no data collection efforts by HBI will commence unless either (i) MFI has obtained commitments in writing for the purchase of the MFI Multi-Client Study sufficient to provide revenues resulting in royalties to HBI at least equal to the Use Fee, Access Fee, and Survey Fee that would, but for Section 5.5(d), be payable in connection with such MFI Multi-Client Study pursuant to Section 2.4(b) hereof, or (ii) MFI has agreed to pay HBI minimum royalties, whether or not earned in connection with revenues from the particular MFI Multi-Client Study at least equal to the Use Fee, Access Fee, and Survey Fee that would, but for Section 5.5(d), be payable in connection with such MFI Multi-Client Study. (d) MFI shall pay to HBI [Confidential Information. Intentionally omitted and filed separately with the Securities and Exchange Commission] based upon all [Confidential Information. Intentionally omitted and filed separately with the Securities and Exchange Commission] received with respect to the [Confidential Information. Intentionally omitted and filed separately with the Securities and Exchange Commission]. The [Confidential Information. Intentionally omitted and filed separately with the Securities and Exchange Commission] shall be at least the minimum royalty required by Sec...
View SourceView Similar (2)

Related to DEVELOPMENT AND CONDUCT OF MFI MULTI-CLIENT STUDIES

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection ▇▇▇▇▇; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Research Program The term “

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.